huntingtin-lowering
uniQure’s Gene Therapy AMT-130 Significantly Slows Huntington’s Progression in Pivotal Trial
Gene therapy; uniQure; AMT-130; Huntington’s disease; clinical trial; disease progression; FDA approval; huntingtin-lowering; neurodegeneration